Exact Mass: 630.3451

Remikiren

C33H50N4O6S (630.3451)

Remikiren is only found in individuals that have used or taken this drug. It is an orally active, high specificity renin inhibitor. Several in vivo experiments have shown that remikiren is specific for renin and does not decrease arterial pressure by an unrelated mechanism. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09X - Other agents acting on the renin-angiotensin system > C09XA - Renin-inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

Finaconitine

C33H46N2O10 (630.3152)

2,3,23-Triacetylsericic acid

C36H54O9 (630.3768)

2,3,23-Triacetylsericic acid is found in coffee and coffee products. 2,3,23-Triacetylsericic acid is isolated from Quercus ilex (holly oak Isolated from Quercus ilex (holly oak). 2,3,23-Triacetylsericic acid is found in coffee and coffee products and fats and oils.

Ganoderic acid Mb

C36H54O9 (630.3768)

Constituent of cultured mycelium of Ganoderma lucidum (reishi). 3a,15a,22S-Triacetoxy-7a-hydroxylanosta-8,24E-dien-26-oic acid is found in mushrooms. Ganoderic acid Mb is found in mushrooms. Ganoderic acid Mb is a metabolite of Ganoderma lucidum (reishi

Goshonoside F4

C32H54O12 (630.3615)

Goshonoside F4 is found in fruits. Goshonoside F4 is a constituent of Rubus foliolosus (Ceylon raspberry). Constituent of Rubus foliolosus (Ceylon raspberry). Goshonoside F4 is found in fruits.

(R)-6'-O-(4-Geranyloxy-2-hydroxycinnamoyl)-marmin

C38H46O8 (630.3193)

(R)-6-O-(4-Geranyloxy-2-hydroxycinnamoyl)-marmin is found in citrus. (R)-6-O-(4-Geranyloxy-2-hydroxycinnamoyl)-marmin is a constituent of Citrus hassaku juice oil. Constituent of Citrus hassaku juice oil. (R)-6-O-(4-Geranyloxy-2-hydroxycinnamoyl)-marmin is found in citrus.

Goshonoside F7

C32H54O12 (630.3615)

Goshonoside F7 is found in fruits. Goshonoside F7 is a constituent of Rubus foliolosus (Ceylon raspberry). Constituent of Rubus foliolosus (Ceylon raspberry). Goshonoside F7 is found in fruits.

Lyciumoside I

C32H54O12 (630.3615)

Constituent of Lycium chinense (Chinese boxthorn). Lyciumoside I is found in tea, coffee and coffee products, and herbs and spices. Lyciumoside I is found in coffee and coffee products. Lyciumoside I is a constituent of Lycium chinense (Chinese boxthorn).

Ganoderic acid Mc

C36H54O9 (630.3768)

Ganoderic acid Mc is found in mushrooms. Ganoderic acid Mc is a metabolite of Ganoderma lucidum (reishi Metabolite of Ganoderma lucidum (reishi). Ganoderic acid Mc is found in mushrooms.

Chapso

C32H58N2O8S (630.3914)

Gambogenic Acid

C38H46O8 (630.3193)

Peridinin

C39H50O7 (630.3556)

PA(10:0/20:3(6,8,11)-OH(5))

C33H59O9P (630.3896)

PA(10:0/20:3(6,8,11)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:3(6,8,11)-OH(5)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 5-hydroxyeicosatetrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:3(6,8,11)-OH(5)/10:0)

C33H59O9P (630.3896)

PA(20:3(6,8,11)-OH(5)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(6,8,11)-OH(5)/10:0), in particular, consists of one chain of one 5-hydroxyeicosatetrienoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(12:0/18:2(10E,12Z)+=O(9))

C33H59O9P (630.3896)

PA(12:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:2(10E,12Z)+=O(9)/12:0)

C33H59O9P (630.3896)

PA(18:2(10E,12Z)+=O(9)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/12:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(12:0/18:2(9Z,11E)+=O(13))

C33H59O9P (630.3896)

PA(12:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:2(9Z,11E)+=O(13)/12:0)

C33H59O9P (630.3896)

PA(18:2(9Z,11E)+=O(13)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/12:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(12:0/18:3(10,12,15)-OH(9))

C33H59O9P (630.3896)

PA(12:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:3(10,12,15)-OH(9)/12:0)

C33H59O9P (630.3896)

PA(18:3(10,12,15)-OH(9)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/12:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(12:0/18:3(9,11,15)-OH(13))

C33H59O9P (630.3896)

PA(12:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:3(9,11,15)-OH(13)/12:0)

C33H59O9P (630.3896)

PA(18:3(9,11,15)-OH(13)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/12:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C31H51O11P (630.3169)

PA(8:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/8:0)

C31H51O11P (630.3169)

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/8:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-12:0/18:2(10E,12Z)+=O(9))

C33H59O9P (630.3896)

PA(i-12:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:2(10E,12Z)+=O(9)/i-12:0)

C33H59O9P (630.3896)

PA(18:2(10E,12Z)+=O(9)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/i-12:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-12:0/18:2(9Z,11E)+=O(13))

C33H59O9P (630.3896)

PA(i-12:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:2(9Z,11E)+=O(13)/i-12:0)

C33H59O9P (630.3896)

PA(18:2(9Z,11E)+=O(13)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/i-12:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-12:0/18:3(10,12,15)-OH(9))

C33H59O9P (630.3896)

PA(i-12:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:3(10,12,15)-OH(9)/i-12:0)

C33H59O9P (630.3896)

PA(18:3(10,12,15)-OH(9)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/i-12:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-12:0/18:3(9,11,15)-OH(13))

C33H59O9P (630.3896)

PA(i-12:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:3(9,11,15)-OH(13)/i-12:0)

C33H59O9P (630.3896)

PA(18:3(9,11,15)-OH(13)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/i-12:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

gambogenic acid

C38H46O8 (630.3193)

Gambogenic acid is an active ingredient in gamboge, with anticancer activity. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination[1]. Gambogenic acid is an active ingredient in gamboge, with anticancer activity. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination[1].

Gambogenic

C38H46O8 (630.3193)

Gambogenic acid is an active ingredient in gamboge, with anticancer activity. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination[1]. Gambogenic acid is an active ingredient in gamboge, with anticancer activity. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination[1].

Dysoxylin C

C35H50O10 (630.3404)

(-)-Pleiomutine

C41H50N4O2 (630.3934)

Macrophyllic acid

C40H54O6 (630.392)

Pestalazine A

C37H38N6O4 (630.2954)

Pestalazine B

C37H38N6O4 (630.2954)

Peridinin 5,8-furanoxide

C39H50O7 (630.3556)

Cussovantoside D

C32H54O12 (630.3615)

Longithorone A

C42H46O5 (630.3345)

3,13-Di-O-beta-D-glucopyranosilgeranyllinalol

C32H54O12 (630.3615)

Cinnafragrin B

C35H50O10 (630.3404)

Adociasulfate 9

C36H54O7S (630.359)

Isogambogenic acid

C38H46O8 (630.3193)

Bryoferulic acid

C40H54O6 (630.392)

Peridinin

C39H50O7 (630.3556)

D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids Window width to select the precursor ion was 3 Da.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan. Window width to select the precursor ion was 3 Da.; CONE_VOLTAGE was 20 V.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan. Window width to select the precursor ion was 3 Da.; CONE_VOLTAGE was 10 V.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.

N-demethylaccedinisine

C40H46N4O3 (630.357)

dimethyl 2,3-bis[5-(3,7-dimethylocta-2,6-dienyl)-3,6-dioxocyclohexa-1,4-dienyl]succinate|lettowiaquinone

C38H46O8 (630.3193)

ajugatakasin A

C34H46O11 (630.304)

A diterpene lactone isolated from the whole plants of Ajuga ciliata.

cambogin

C40H54O6 (630.392)

gomojoside H

C32H54O12 (630.3615)

21-desethyl-21-cyclobutyl spinosyn D 17-pseudoaglycone

C36H54O9 (630.3768)

3,3-(3-ethylidene-16-hydroxy-2,7,13,17-tetramethyl-1,19-dioxo-18-vinyl-1,2,3,15,16,19,22,24-octahydro-21H-biline-8,12-diyl)-bis-propionic acid dimethyl ester|Aplysioviolin

C35H42N4O7 (630.3053)

L009956

C37H38N6O4 (630.2954)

16beta,17-dihydroxy-ent-kauran-19-oic acid 19-[alpha-L-arabinopyranosyl-(1->2)-beta-D-glucopyranosyl] ester

C31H50O13 (630.3251)

12-(deca-2,4-dienoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one|EBI-61

C35H50O10 (630.3404)

beauverolide Ka

C37H50N4O5 (630.3781)

Hazuntiphyllidine

C40H46N4O3 (630.357)

(-)-(2S,3S,4R)-10-de-O-carbamoyl-12-O-carbamoylstreptothricin E|Streptothricin-E

C25H46N10O9 (630.3449)

3beta-bryoferulic acid|3beta-O-trans-ferulyl-D:C-friedooleana-7,9(11)-diene-29-oic acid|3beta-[(E)-feruloyloxy]-D:C-friedooleane-7,9(11)-dien-29-oic acid

C40H54O6 (630.392)

1-O-[2-O-acetyl-alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranosyl]-12-acetoxy-(2E,6E)-farnesol|crenulatoside F

C31H50O13 (630.3251)

C28H54O15

C28H54O15 (630.3463)

1-O-[2,3-di-O-acetyl-alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranosyl]-12-hydroxy-(2E,6E)-farnesol|crenulatoside E

C31H50O13 (630.3251)

Hybrimycin A1|Hybrimycin A2|Hybrimycin B1|Hybrimycin B2

C23H46N6O14 (630.3072)

Urs-11-en-28-oic acid,13-hydroxy-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]oxy]-, g-lactone, (3b)- (9CI)

C40H54O6 (630.392)

Vernonioside A3

C35H50O10 (630.3404)

Hazuntiphylline

C40H46N4O3 (630.357)

Streptothricin E

C25H46N10O9 (630.3449)

A natural product found in Streptomyces sp. I08A 1776.

mitrarioside A1

C32H54O12 (630.3615)

aphanalide H

C34H46O11 (630.304)

(22R)-27-hydroxy-7alpha-methoxy-1-oxowitha-3,5,24-trienolide 27-O-beta-D-glucopyranoside

C35H50O10 (630.3404)

aphanalide A

C34H46O11 (630.304)

alphapolynin F

C34H46O11 (630.304)

walsogyne D

C34H46O11 (630.304)

C38H50N2O6

C38H50N2O6 (630.3669)

(3beta)-17-carboxy-28,30-dinoroleana-12,20(29)-dien-3-yl beta-D-glucopyranosiduronic acid 6-methyl ester|(3beta)-3-hydroxy-noroleana-12,20(29)-dien-28-oic acid 3- (beta-D-glucopyranosiduronic acid 6-methyl ester)

C36H54O9 (630.3768)

21-(E)-feruloyloxy-5alpha-cycloart-24-ene-3,23-dione

C40H54O6 (630.392)

diacetyldimethylbartogenate|dimethyl 2alpha,3beta-diacetyl-19alpha-hydroxybartogenate

C36H54O9 (630.3768)

12-Hydroxystrychnobiline

C40H46N4O3 (630.357)

Ekebergin

C34H46O11 (630.304)

spinosyn delta

C36H54O9 (630.3768)

oligoporin A

C36H54O9 (630.3768)

cytosporolide C

C35H50O10 (630.3404)

1,2-dihydro-5beta,21alpha-dihydroxy-21-methyl-6alpha,7alpha-epoxy-9,13,14-ortho-1alpha-(33E-pentadecenoate)-resiniferonol-36-oic acid|kirkinine E

C36H54O9 (630.3768)

1-O-[3-O-acetyl-alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranosyl]-12-acetoxy-(2E,6E)-farnesol|crenulatoside G

C31H50O13 (630.3251)

19alpha-hydroxy-2alpha,3alpha,24-triacetoxyurs-12-en-28-oic acid

C36H54O9 (630.3768)

19-hydroxyingol 3,12-diacetate 7,8-ditiglate

C34H46O11 (630.304)

all-trans-(3S,5R,6R,3S,5R,6S)-peridinin

C39H50O7 (630.3556)

Lys Ile Gln Asp Lys

C27H50N8O9 (630.3701)

Leu Ala His Tyr Asn

C29H42N8O8 (630.3125)

Ser Leu Arg Leu Asp

C27H50N8O9 (630.3701)

His Arg Tyr Arg

C27H42N12O6 (630.335)

Tyr His Arg Arg

C27H42N12O6 (630.335)

iso-GNA

C38H46O8 (630.3193)

Pleiomutine

C41H50N4O2 (630.3934)

His Arg Arg Tyr

C27H42N12O6 (630.335)

His Tyr Arg Arg

C27H42N12O6 (630.335)

Asn Arg Arg Trp

C27H42N12O6 (630.335)

Asn Arg Trp Arg

C27H42N12O6 (630.335)

Asn Trp Arg Arg

C27H42N12O6 (630.335)

Arg His Arg Tyr

C27H42N12O6 (630.335)

Arg His Tyr Arg

C27H42N12O6 (630.335)

Arg Asn Arg Trp

C27H42N12O6 (630.335)

Arg Asn Trp Arg

C27H42N12O6 (630.335)

Arg Arg His Tyr

C27H42N12O6 (630.335)

Arg Arg Asn Trp

C27H42N12O6 (630.335)

Arg Arg Trp Asn

C27H42N12O6 (630.335)

Arg Arg Tyr His

C27H42N12O6 (630.335)

Arg Trp Asn Arg

C27H42N12O6 (630.335)

Arg Trp Arg Asn

C27H42N12O6 (630.335)

Arg Tyr His Arg

C27H42N12O6 (630.335)

Arg Tyr Arg His

C27H42N12O6 (630.335)

Trp Asn Arg Arg

C27H42N12O6 (630.335)

Trp Arg Asn Arg

C27H42N12O6 (630.335)

Trp Arg Arg Asn

C27H42N12O6 (630.335)

Tyr Arg His Arg

C27H42N12O6 (630.335)

Tyr Arg Arg His

C27H42N12O6 (630.335)

KIQDK

C27H50N8O9 (630.3701)

DIHYDROGAMBOGIC ACID

C38H46O8 (630.3193)

2,3,23-Triacetylsericic acid

C36H54O9 (630.3768)

Ganoderic acid Mb

C36H54O9 (630.3768)

Ganoderic acid Mc

C36H54O9 (630.3768)

Goshonoside F4

C32H54O12 (630.3615)

Goshonoside F7

C32H54O12 (630.3615)

(R)-6-O-(4-Geranyloxy-2-hydroxy)-cinnamoylmarmin

C38H46O8 (630.3193)

Lyciumoside I

C32H54O12 (630.3615)

Nor-peridinin1

C39H50O7 (630.3556)

Nor-peridinin2

C39H50O7 (630.3556)

CHAPSO

C32H58N2O8S (630.3914)

hexadecanoate,tin(2+)

C32H62O4Sn (630.367)

[4-(4-butyl-N-[4-[4-(N-(4-butylphenyl)anilino)phenyl]phenyl]anilino)phenyl]methanol

C45H46N2O (630.361)

Tereticornate A

C40H54O6 (630.392)

2-[3-[5,5-dimethyl-3-[4-(1,3,3-trimethylindol-1-ium-2-yl)but-3-en-2-ylidene]cyclohexen-1-yl]but-2-enylidene]-1,3,3-trimethylindole,perchlorate

C38H47ClN2O4 (630.3224)

Boc-Gln-Ala-Arg-7-Amino-4-Methylcoumarin

C29H42N8O8 (630.3125)

L-Urobilin

C33H47ClN4O6 (630.3184)

L-Urobilin or Stercobilin is a byproduct of bilirubin degradation. It is a tetrapyrrole chemical compound, responsible for the typical brown color of human feces. It is created by bacterial action on bilirubin and subsequent oxidation. In plasma virtually all the bilirubin is tightly bound to plasma proteins, largely albumin, because it is only sparingly soluble in aqueous solutions at physiological pH. In the sinusoids unconjugated bilirubin dissocates from albumin, enters the liver cells across the cell membrane through non-ionic diffusion to the smooth endoplasmatic reticulum, where it is converted to a water-soluble ester glucuronide by bilirubin UDP-glucuronyl transferase. Following conjugation, bilirubin is transferred rapidly across the canalicular membrane into the bile canaliculi. In the intestinal tract bilirubin is reduced to urobilinogen, which is subsequently reabsorbed to some extent into the enterohepatic circulation, removed from plasma by the liver and excreted unchanged in the bile. The residual part of urobilinogen is further reduced to urobilin, stercobilin and dipyrrolmethenes and excreted in the feces. [HMDB]

Oleanoic acid 3-O-glucuronide

C36H54O9-2 (630.3768)

3-Hydroxy-4-methyl-anthranilate pentapeptide lactone

C31H46N6O8 (630.3377)

(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2Z,6E,10E)-2,6,10,14-tetramethyl-14-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadeca-2,6,10,15-tetraenoxy]oxane-3,4,5-triol

C32H54O12 (630.3615)

PA(12:0/18:2(10E,12Z)+=O(9))

C33H59O9P (630.3896)

PA(18:2(10E,12Z)+=O(9)/12:0)

C33H59O9P (630.3896)

PA(12:0/18:2(9Z,11E)+=O(13))

C33H59O9P (630.3896)

PA(18:2(9Z,11E)+=O(13)/12:0)

C33H59O9P (630.3896)

PA(i-12:0/18:2(10E,12Z)+=O(9))

C33H59O9P (630.3896)

PA(18:2(10E,12Z)+=O(9)/i-12:0)

C33H59O9P (630.3896)

PA(i-12:0/18:2(9Z,11E)+=O(13))

C33H59O9P (630.3896)

PA(18:2(9Z,11E)+=O(13)/i-12:0)

C33H59O9P (630.3896)

[(2R)-1-decanoyloxy-3-phosphonooxypropan-2-yl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate

C33H59O9P (630.3896)

[(2R)-2-decanoyloxy-3-phosphonooxypropyl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate

C33H59O9P (630.3896)

[(2R)-1-dodecanoyloxy-3-phosphonooxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

C33H59O9P (630.3896)

[(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

C33H59O9P (630.3896)

[(2R)-1-dodecanoyloxy-3-phosphonooxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

C33H59O9P (630.3896)

[(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

C33H59O9P (630.3896)

PA(i-12:0/18:3(10,12,15)-OH(9))

C33H59O9P (630.3896)

PA(18:3(10,12,15)-OH(9)/i-12:0)

C33H59O9P (630.3896)

PA(i-12:0/18:3(9,11,15)-OH(13))

C33H59O9P (630.3896)

PA(18:3(9,11,15)-OH(13)/i-12:0)

C33H59O9P (630.3896)

PA(8:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C31H51O11P (630.3169)

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/8:0)

C31H51O11P (630.3169)

CID 6381892

C39H50O7 (630.3556)

Jasplakinolide Q

C36H46N4O6 (630.3417)

A cyclodepsipeptide isolated from Jaspis splendens.

ethyl (2E,4S)-4-[(2S)-2-[(2S,3S)-2-{[(benzyloxy)carbonyl]amino}-3-(tert-butoxy)butanamido]-4-methylpentanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate

C33H50N4O8 (630.3628)

(-)-(2S,3S,4R)-10-de-O-carbamoyl-12-O-carbamoylstreptothricin E

C25H46N10O9 (630.3449)

A natural product found in Streptomyces sp. I08A 1776.

lumutinine D

C40H46N4O3 (630.357)

A natural product found in Alstonia macrophylla.

1-[(3S,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(1-naphthalenyl)urea

C37H50N4O5 (630.3781)

N-[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(1-oxo-2-phenylethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C36H46N4O6 (630.3417)

N-(2-aminophenyl)-4-[[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-9-[[oxo-(propan-2-ylamino)methyl]amino]-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl-methylamino]methyl]benzamide

C35H46N6O5 (630.353)

1-[(3S,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(1-naphthalenyl)urea

C37H50N4O5 (630.3781)

[(2R,3S,4S,5R,6R)-6-[(2S,3S,4R)-2-formamido-3,4-dihydroxy-15-methylhexadecoxy]-3,4,5-trihydroxyoxan-2-yl]methyl 2-(methylazaniumyl)ethyl phosphate

C27H55N2O12P (630.3492)

methyl (1S,9R,16S,18R,21S)-6-[(15R,17S,19R)-15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraen-17-yl]-2-methyl-2,12-diazahexacyclo[14.2.2.19,12.01,9.03,8.016,21]henicosa-3(8),4,6-triene-18-carboxylate

C41H50N4O2 (630.3934)

[(2R,3S,4S,5R,6R)-6-[(2S,3S,4R)-2-formamido-3,4-dihydroxy-15-methylhexadecoxy]-3,4,5-trihydroxyoxan-2-yl]methyl 2-(methylamino)ethyl hydrogen phosphate

C27H55N2O12P (630.3492)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C33H59O9P (630.3896)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] undecanoate

C33H59O9P (630.3896)

[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C32H55O10P (630.3533)

[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C32H55O10P (630.3533)

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C32H55O10P (630.3533)

[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C32H55O10P (630.3533)

[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C32H55O10P (630.3533)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C32H55O10P (630.3533)

[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C32H55O10P (630.3533)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C32H55O10P (630.3533)

[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C32H55O10P (630.3533)

[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C32H55O10P (630.3533)

[1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C32H55O10P (630.3533)

[1-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C35H51O8P (630.3321)

[1-[(E)-dec-4-enoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C32H55O10P (630.3533)

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C35H51O8P (630.3321)

[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

C32H55O10P (630.3533)

methyl (2S)-2-[(2R,3E,12bS)-3-ethylidene-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-[(2R,3R)-3-ethyl-2-(2-hydroxyethyl)-1,2,3,4-tetrahydroindolo[2,3-a]quinolizin-7-yl]propanoate

C40H46N4O3 (630.357)

Remikiren

C33H50N4O6S (630.3451)

C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09X - Other agents acting on the renin-angiotensin system > C09XA - Renin-inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

(R)-6-O-(4-Geranyloxy-2-hydroxycinnamoyl)-marmin

C38H46O8 (630.3193)

SQMG 22:5

C31H50O11S (630.3074)

DGGA 23:2;O

C32H54O12 (630.3615)

PA O-29:5;O3

C32H55O10P (630.3533)

PA O-30:4;O2

C33H59O9P (630.3896)

PA P-18:0/12:3;O2

C33H59O9P (630.3896)

PA P-18:1/11:3;O3

C32H55O10P (630.3533)

PA P-18:1/12:2;O2

C33H59O9P (630.3896)

PA 16:0/13:4;O2

C32H55O10P (630.3533)

PA 16:1/13:3;O2

C32H55O10P (630.3533)

PA 18:0/12:3;O

C33H59O9P (630.3896)

PA 20:0/9:4;O2

C32H55O10P (630.3533)

PA 20:2/8:3;O3

C31H51O11P (630.3169)

PA 20:3/8:2;O3

C31H51O11P (630.3169)

PA 20:3/9:1;O2

C32H55O10P (630.3533)

PA 22:0/8:3;O

C33H59O9P (630.3896)

PA 22:1/7:3;O2

C32H55O10P (630.3533)

PA 22:2/7:2;O2

C32H55O10P (630.3533)

PA 22:2/8:1;O

C33H59O9P (630.3896)

PA 28:5;O3

C31H51O11P (630.3169)

PA 29:4;O2

C32H55O10P (630.3533)

PA 30:3;O

C33H59O9P (630.3896)

LPGP P-22:1

C28H56O11P2 (630.3298)

PG O-25:6;O2

C31H51O11P (630.3169)

PG O-26:5;O

C32H55O10P (630.3533)

PG P-16:1/9:4;O2

C31H51O11P (630.3169)

PG P-18:1/7:4;O2

C31H51O11P (630.3169)

PG P-18:1/8:3;O

C32H55O10P (630.3533)

PG 18:2/7:3;O

C31H51O11P (630.3169)

PG 20:4/5:1;O

C31H51O11P (630.3169)

PG 25:5;O

C31H51O11P (630.3169)

PG 22:4/4:0

C32H55O10P (630.3533)

PG 24:4/2:0

C32H55O10P (630.3533)

PG 26:4

C32H55O10P (630.3533)

LPI 18:1;O2

C27H51O14P (630.3016)

PEth 28:3;O

C33H59O9P (630.3896)

PM 29:3;O

C33H59O9P (630.3896)

ST 25:1;O7;GlcA

C31H50O13 (630.3251)

ST 26:0;O6;GlcA

C32H54O12 (630.3615)

ST 28:6;O5;GlcA

C34H46O11 (630.304)

ST 29:5;O4;GlcA

C35H50O10 (630.3404)

ST 25:2;O8;Hex

C31H50O13 (630.3251)

ST 26:1;O7;Hex

C32H54O12 (630.3615)

ST 28:7;O6;Hex

C34H46O11 (630.304)

ST 29:6;O5;Hex

C35H50O10 (630.3404)

n-{1-[(2r,5s,6r)-5-{[(2r,3r,4s,5s,6r)-5-(dimethylamino)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]-2-hydroxypyrimidin-4-ylidene}-4-[(4r)-4-(hydroxymethyl)-4-methyl-5-oxoimidazolidin-1-yl]benzamide

C30H42N6O9 (630.3013)

18-ethyl-6,12-dihydroxy-4-(4-hydroxyphenyl)-7-(1h-indol-3-ylmethyl)-8,10,13,15,17-pentamethyl-1-oxa-5,8,11-triazacyclooctadeca-5,11,15-triene-2,9-dione

C36H46N4O6 (630.3417)

(1s)-2-[(1r,4r,4ar,5s,6r,8s,8ar)-8-(acetyloxy)-8a-[(acetyloxy)methyl]-5,6-dimethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-5-yl]-1-(5-oxo-2h-furan-3-yl)ethyl 2-methylbut-2-enoate

C34H46O11 (630.304)

(1s,3r,4s,5s,7r,8s,9r,12s,13s,16s)-16-(acetyloxy)-13-(furan-3-yl)-5-hydroxy-7-(2-methoxy-2-oxoethyl)-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-4-yl 3-methylbutanoate

C34H46O11 (630.304)

1-[(12e)-12-ethylidene-10-{14-ethylidene-10-oxa-8,16-diazahexacyclo[11.5.2.1¹,⁸.0²,⁷.0¹⁶,¹⁹.0¹²,²¹]henicosa-2,4,6-trien-9-yl}-6-hydroxy-8,14-diazapentacyclo[9.5.2.0¹,⁹.0²,⁷.0¹⁴,¹⁷]octadeca-2,4,6-trien-8-yl]ethanone

C40H46N4O3 (630.357)

methyl (1s,12s,14r,15z,18s)-15-ethylidene-12-[(1s,14r,15z)-15-ethylidene-13-(hydroxymethyl)-3-methyl-3,17-diazapentacyclo[12.3.1.0²,¹⁰.0⁴,⁹.0¹²,¹⁷]octadeca-2(10),4,6,8-tetraen-7-yl]-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C40H46N4O3 (630.357)

n-{3-[(2r,5r,8s,11r,14s)-3,6,9,12,15-pentahydroxy-14-[(4-hydroxyphenyl)methyl]-5,11-diisopropyl-8-(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1(15),3,6,9,12-pentaen-2-yl]propyl}guanidine

C31H50N8O6 (630.3853)

(1s)-2-[(1r,4r,4ar,5s,6r,8s,8ar)-8-(acetyloxy)-8a-[(acetyloxy)methyl]-5,6-dimethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-5-yl]-1-(5-oxo-2h-furan-3-yl)ethyl (2z)-2-methylbut-2-enoate

C34H46O11 (630.304)

(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-{[(2z,6e,10e)-2,6,10,14-tetramethyl-14-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexadeca-2,6,10,15-tetraen-1-yl]oxy}oxane-3,4,5-triol

C32H54O12 (630.3615)

2-hydroxy-2,6-dimethyl-8-[(2-oxochromen-7-yl)oxy]oct-6-en-3-yl 3-{4-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]-2-hydroxyphenyl}prop-2-enoate

C38H46O8 (630.3193)

(3s)-n-[(2r,3r,4s,5r,6r)-2-{[(3as,7r,7as)-4,7-dihydroxy-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl]amino}-4,5-dihydroxy-6-[(c-hydroxycarbonimidoyloxy)methyl]oxan-3-yl]-3-amino-6-{[(3s)-3,6-diamino-1-hydroxyhexylidene]amino}hexanimidic acid

C25H46N10O9 (630.3449)

(2s,3ar,5as,5bs,9r,13s,14r,16as,16bs)-9-[(1e)-but-1-en-1-yl]-13-hydroxy-4,14-dimethyl-2-{[(2r,3r,4r,5s,6s)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy}-1h,2h,3h,3ah,5ah,5bh,6h,9h,10h,11h,12h,13h,14h,16ah,16bh-as-indaceno[3,2-d]oxacyclododecane-7,15-dione

C36H54O9 (630.3768)

(2r,3r,4s,5r,6r)-2-{[(1r,4ar,5s,8s,8ar)-8-hydroxy-1,4a-dimethyl-5-[(3e)-3-methyl-5-{[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}pent-3-en-1-yl]-6-methylidene-hexahydro-2h-naphthalen-1-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C32H54O12 (630.3615)

5-methoxy-2-(methoxymethyl)-6-[(1,2,4,5,6-pentamethoxyhexan-3-yl)oxy]-4-[(3,4,5-trimethoxy-6-methyloxan-2-yl)oxy]oxan-3-ol

C28H54O15 (630.3463)

(1r,4r,7s,9s)-4-benzyl-9-(3-{[(2s,5r)-3,6-dihydroxy-5-(2-methylpropyl)-2,5-dihydropyrazin-2-yl]methyl}indol-1-yl)-6-hydroxy-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C37H38N6O4 (630.2954)

(12s,14s,15s,17r,31s,33s,34s,36r,41s,42s)-14,33-diethyl-10,16,35-trioxa-8,19,29,38-tetraazatetradecacyclo[31.7.1.1⁸,¹².1¹⁴,¹⁹.0¹,⁹.0²,⁷.0⁹,³¹.0¹¹,²².0¹¹,²⁹.0¹⁵,¹⁷.0²³,²⁸.0³⁴,³⁶.0³⁸,⁴¹.0²²,⁴²]tritetraconta-2,4,6,23,25,27-hexaene

C40H46N4O3 (630.357)

(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e)-11-[(2z)-4-[(1e)-2-[(1s,4r,6r)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaen-1-ylidene]-3,5,5-trimethylcyclohexyl acetate

C39H50O7 (630.3556)

n-[1-(5-{[5-(dimethylamino)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl)-2-hydroxypyrimidin-4-ylidene]-4-[4-(hydroxymethyl)-4-methyl-5-oxoimidazolidin-1-yl]benzamide

C30H42N6O9 (630.3013)

[(1r,2r,3s,4e,6r,9s,10s,12s,21r)-21-hexyl-9,10,17-trihydroxy-3-methoxy-8,8,12,24-tetramethyl-15-oxo-13,14,22-trioxapentacyclo[14.6.2.0²,¹².0⁶,⁹.0¹⁹,²³]tetracosa-4,16,18,23-tetraen-5-yl]methyl acetate

C35H50O10 (630.3404)

3-hydroxy-4-{11-[4-(2-{4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl}ethenyl)-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaen-1-ylidene}-3,5,5-trimethylcyclohexyl acetate

C39H50O7 (630.3556)

(3s)-n-[(2r,3r,4s,5r,6r)-2-{[(3as,7r,7as)-4,7-dihydroxy-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl]amino}-4-hydroxy-5-(c-hydroxycarbonimidoyloxy)-6-(hydroxymethyl)oxan-3-yl]-3-amino-6-{[(3s)-3,6-diamino-1-hydroxyhexylidene]amino}hexanimidic acid

C25H46N10O9 (630.3449)

n-[(2s,3s)-2-[(s)-hydroxy({[(1s)-1-[(3s)-8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl]-13-methyltetradecanimidic acid

C35H54N2O8 (630.388)

(2r,3r,4s,5s,6r)-2-{[(1s,4as,5r,8as)-1,4a-dimethyl-5-[(3e)-3-methyl-5-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pent-3-en-1-yl]-6-methylidene-hexahydro-2h-naphthalen-1-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C32H54O12 (630.3615)

(2r,4as,6as,8ar,10s,12as,14as,14br)-10-{[(2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy}-2,4a,6a,9,9,12a,14a-heptamethyl-1,3,4,5,6,8,8a,10,11,12,14,14b-dodecahydropicene-2-carboxylic acid

C40H54O6 (630.392)

(8z,16e,21e,23e,27z)-9,17,24,28-tetramethyl-13,32,34,37-tetraoxopentacyclo[28.2.2.2¹¹,¹⁴.1⁵,¹⁹.0³,²⁰]heptatriaconta-1(33),5(35),8,11,14(36),16,21,23,27,30-decaene-20-carbaldehyde

C42H46O5 (630.3345)

(2z,6r)-6-[(1r,3as,5ar,9as,11r,11ar)-3a,6,6,9a,11a-pentamethyl-7-oxo-11-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

(3e,6r,7r,8e,10e,14z,23s,28z)-4,11,15,29-tetramethyl-19,33,35,37-tetraoxopentacyclo[29.2.2.1⁶,²⁵.1¹⁷,²¹.0⁷,²³]heptatriaconta-1(34),3,8,10,14,17,20,25(36),28,31-decaene-7-carbaldehyde

C42H46O5 (630.3345)

(1r,4r,7s,9r)-4-benzyl-9-(3-{[(2s,5r)-3,6-dihydroxy-5-(2-methylpropyl)-2,5-dihydropyrazin-2-yl]methyl}-1h-indol-7-yl)-6-hydroxy-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C37H38N6O4 (630.2954)

6-(3a,6,6,9a,11a-pentamethyl-7-oxo-11-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

butyl (6r)-6-[(1r,3ar,4s,5ar,7s,9as,11s,11ar)-11-(acetyloxy)-4,7-dihydroxy-3a,6,6,9a,11a-pentamethyl-3,10-dioxo-1h,2h,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxoheptanoate

C36H54O9 (630.3768)

n-(5-{[(2r,4s,5r,6r)-2-{[(3as,7r,7as)-4,7-dihydroxy-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl]amino}-4-hydroxy-5-(c-hydroxycarbonimidoyloxy)-6-(hydroxymethyl)oxan-3-yl]-c-hydroxycarbonimidoyl}-4-aminopentyl)-3,6-diaminohexanimidic acid

C25H46N10O9 (630.3449)

2,2'-dihydroxy-1,1'-diisopropyl-4b,4'b,8,8'-tetramethyl-5h,5'h,6h,6'h,7h,7'h,8ah,8'ah,9h,9'h,10h,10'h-[3,3'-biphenanthrene]-8,8'-dicarboxylic acid

C40H54O6 (630.392)

(1s,3r)-4-[(3e,5e,7e,9e)-11-[(2z)-4-[(2s,6s,7ar)-6-hydroxy-4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-2-yl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaen-1-ylidene]-3-hydroxy-3,5,5-trimethylcyclohexyl acetate

C39H50O7 (630.3556)

2-[(8-hydroxy-1,4a-dimethyl-5-{3-methyl-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]pent-3-en-1-yl}-6-methylidene-hexahydro-2h-naphthalen-1-yl)methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C32H54O12 (630.3615)

4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-(5-oxooxolan-3-yl)-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl 2-methylbutanoate

C35H50O10 (630.3404)

5-(acetyloxy)-6-[3,7-bis(acetyloxy)-4-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

(2s,3r,4r,5r,6s)-2-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-2-{[(1s,4s,5r,9s,10r,13r,14s)-14-hydroxy-14-(hydroxymethyl)-5,9-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methoxy}-6-(hydroxymethyl)oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C32H54O12 (630.3615)

4-benzyl-9-(3-{[3,6-dihydroxy-5-(2-methylpropyl)-2,5-dihydropyrazin-2-yl]methyl}indol-1-yl)-6-hydroxy-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C37H38N6O4 (630.2954)

(1s,4s,7s,9s)-9-[(1s,4s,7s,9s)-4-benzyl-6-hydroxy-3-oxo-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-9-yl]-6-hydroxy-4-(2-methylpropyl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C37H38N6O4 (630.2954)

{21-hexyl-9,10,17-trihydroxy-3-methoxy-8,8,12,24-tetramethyl-15-oxo-13,14,22-trioxapentacyclo[14.6.2.0²,¹².0⁶,⁹.0¹⁹,²³]tetracosa-4,16,18,23-tetraen-5-yl}methyl acetate

C35H50O10 (630.3404)

(2r,4as,6as,8ar,10r,12as,14as,14br)-10-{[(2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy}-2,4a,6a,9,9,12a,14a-heptamethyl-1,3,4,5,6,8,8a,10,11,12,14,14b-dodecahydropicene-2-carboxylic acid

C40H54O6 (630.392)

1,4-dimethyl (2r,3s)-2,3-bis({5-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-3,6-dioxocyclohexa-1,4-dien-1-yl})butanedioate

C38H46O8 (630.3193)

(2r,3r,4s,5s,6r)-2-{[(1r,4ar,5s,8s,8ar)-8-hydroxy-1,4a-dimethyl-5-[(3e)-3-methyl-5-{[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}pent-3-en-1-yl]-6-methylidene-hexahydro-2h-naphthalen-1-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C32H54O12 (630.3615)

(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl (1s,4s,5r,9s,10r,13r,14r)-14-hydroxy-14-(hydroxymethyl)-5,9-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

C31H50O13 (630.3251)

(2e,5s,6s)-6-[(1r,3s,3ar,4r,5ar,7r,9as,11ar)-3,7-bis(acetyloxy)-4-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

3-[(2s)-4-[(2e,4e,6s)-6-[(2s,5r,6r)-1,6-dimethyl-8,9-dioxaspiro[bicyclo[3.3.1]nonane-2,2'-oxiran]-3-en-7-yl]-4-methylhepta-2,4-dienoyl]-1-(5-hydroxy-6-methyloxan-2-yl)-3,5-dioxopyrrolidin-2-yl]-n-methylpropanimidic acid; ethane

C34H50N2O9 (630.3516)

(2s,3r,4r,5r,6s)-2-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-2-{[(1r,4s,5r,9r,10r,13s,14r)-14-hydroxy-14-(hydroxymethyl)-5,9-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methoxy}-6-(hydroxymethyl)oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C32H54O12 (630.3615)

(2r,3s,4s,5s,6r)-2-(hydroxymethyl)-6-{[(4r,6e,10e,14s)-2,6,10,14-tetramethyl-14-{[(2s,3s,4s,5s,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexadeca-2,6,10,15-tetraen-4-yl]oxy}oxane-3,4,5-triol

C32H54O12 (630.3615)

(1s,2s,7s,8s,11s,13s,15s)-15-[(1s,4s,4as,8as)-4-(acetyloxy)-1-formyl-1-hydroxy-5,5,8a-trimethyl-4a,6,7,8-tetrahydro-4h-naphthalen-2-yl]-11-methoxy-2,6,6-trimethyl-12,14,16-trioxatetracyclo[8.6.0.0¹,¹³.0²,⁷]hexadec-9-en-8-yl acetate

C35H50O10 (630.3404)

(3r)-n-(2-{[(3as,7r,7as)-4,7-dihydroxy-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl]amino}-4-hydroxy-5-(c-hydroxycarbonimidoyloxy)-6-(hydroxymethyl)oxan-3-yl)-3-amino-6-{[(3r)-3,6-diamino-1-hydroxyhexylidene]amino}hexanimidic acid

C25H46N10O9 (630.3449)

3-hydroxy-4-{11-[4-(6-hydroxy-4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-2-yl)-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaen-1-ylidene}-3,5,5-trimethylcyclohexyl acetate

C39H50O7 (630.3556)

(1s,3br,4r,5ar,9as,9bs,10r,11as)-4-(acetyloxy)-1-[(3s,5r)-5-[(1s)-1,2-dihydroxy-2-methylpropyl]-2-hydroxyoxolan-3-yl]-6,6,9a,11a-tetramethyl-7-oxo-1h,2h,3bh,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-10-yl (2r)-2-methylbutanoate

C36H54O9 (630.3768)

(2r,3r,4s,5s,6r)-2-{[(2r,4as,5r,8as)-1,1,4a-trimethyl-5-[(3e)-3-methyl-5-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pent-3-en-1-yl]-6-methylidene-hexahydro-2h-naphthalen-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C32H54O12 (630.3615)

(2r,3r,4s,5r,6s)-5-methoxy-2-(methoxymethyl)-6-{[(2r,3r,4s,5s)-1,2,4,5,6-pentamethoxyhexan-3-yl]oxy}-4-{[(2s,3r,4r,5s,6s)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy}oxan-3-ol

C28H54O15 (630.3463)

n-{2-[hydroxy({[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl}-13-methyltetradecanimidic acid

C35H54N2O8 (630.388)

(1s,4s,5r,10s,13s,17s)-4,5,9,9,13,19,20-heptamethyl-23-oxo-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-en-10-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C40H54O6 (630.392)

2-{[1,1,4a-trimethyl-5-(3-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pent-3-en-1-yl)-6-methylidene-hexahydro-2h-naphthalen-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C32H54O12 (630.3615)

(1s,4s,5r,8r,10s,13s,14r,17s,18r,19s,20r)-4,5,9,9,13,19,20-heptamethyl-23-oxo-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-en-10-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C40H54O6 (630.392)

(1r,4s,7s)-9-[(1r,4s,7s)-4-benzyl-6-hydroxy-3-oxo-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-9-yl]-6-hydroxy-4-(2-methylpropyl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C37H38N6O4 (630.2954)

8,16,29-trimethyl-13,25,35,38-tetraoxoheptacyclo[25.5.3.2¹¹,¹⁴.1⁶,²⁰.0³,²⁴.0⁵,²².0²⁴,³⁴]octatriaconta-1,8,11,14(37),16,20(36),26,29-octaene-5-carbaldehyde

C42H46O5 (630.3345)

5-(acetyloxy)-6-[4,7-bis(acetyloxy)-3-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

1,4-dimethyl 2,3-bis[5-(3,7-dimethylocta-2,6-dien-1-yl)-3,6-dioxocyclohexa-1,4-dien-1-yl]butanedioate

C38H46O8 (630.3193)

(2s,3r,4r,5r,6s)-2-{[(2r,3r,4s,5r,6r)-4,5-dihydroxy-2-{[(1s,4s,5r,9s,10s,13r,14s)-14-hydroxy-14-(hydroxymethyl)-5,9-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methoxy}-6-(hydroxymethyl)oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C32H54O12 (630.3615)

(2e,5s,6r)-6-[(1r,3s,3ar,4r,5ar,7s,9as,11ar)-4,7-bis(acetyloxy)-3-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

n-(3-{3,6,9,12,15-pentahydroxy-14-[(4-hydroxyphenyl)methyl]-5,11-diisopropyl-8-(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1(15),3,6,9,12-pentaen-2-yl}propyl)guanidine

C31H50N8O6 (630.3853)

(3r,5s,6r,8e,16z,22s,24r,29z,34s)-8,16,29-trimethyl-13,25,35,38-tetraoxoheptacyclo[25.5.3.2¹¹,¹⁴.1⁶,²⁰.0³,²⁴.0⁵,²².0²⁴,³⁴]octatriaconta-1,8,11,14(37),16,20(36),26,29-octaene-5-carbaldehyde

C42H46O5 (630.3345)

10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-1-hydroxy-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C36H54O9 (630.3768)

(4bs,4'bs,8s,8's)-2,2'-dihydroxy-1,1'-diisopropyl-4b,4'b,8,8'-tetramethyl-5h,5'h,6h,6'h,7h,7'h,8ah,8'ah,9h,9'h,10h,10'h-[3,3'-biphenanthrene]-8,8'-dicarboxylic acid

C40H54O6 (630.392)

4-[(1s,2s,13r,15s)-7-(3,7-dimethylocta-2,6-dien-1-yl)-6,8-dihydroxy-17,17-dimethyl-5-(3-methylbut-2-en-1-yl)-10,14-dioxo-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraen-15-yl]-2-methylbut-2-enoic acid

C38H46O8 (630.3193)

2-[(4,5-dihydroxy-2-{[14-hydroxy-14-(hydroxymethyl)-5,9-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methoxy}-6-(hydroxymethyl)oxan-3-yl)oxy]-6-methyloxane-3,4,5-triol

C32H54O12 (630.3615)

(2e,5s,6r)-6-[(1s,3s,3as,4r,5as,7r,9as,11ar)-3,7-bis(acetyloxy)-4-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

(4bs,4'bs,8s,8's,8ar,8'ar)-2,2'-dihydroxy-1,1'-diisopropyl-4b,4'b,8,8'-tetramethyl-5h,5'h,6h,6'h,7h,7'h,8ah,8'ah,9h,9'h,10h,10'h-[3,3'-biphenanthrene]-8,8'-dicarboxylic acid

C40H54O6 (630.392)

9-(but-1-en-1-yl)-13-hydroxy-4,14-dimethyl-2-[(3,4,5-trimethoxy-6-methyloxan-2-yl)oxy]-1h,2h,3h,3ah,5ah,5bh,6h,9h,10h,11h,12h,13h,14h,16ah,16bh-as-indaceno[3,2-d]oxacyclododecane-7,15-dione

C36H54O9 (630.3768)

(2z)-4-[(1s,2s,13s,15r)-7-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,8-dihydroxy-17,17-dimethyl-5-(3-methylbut-2-en-1-yl)-10,14-dioxo-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraen-15-yl]-2-methylbut-2-enoic acid

C38H46O8 (630.3193)

n-{1-[(2r,5s,6r)-5-{[(2r,3r,4s,5s,6r)-5-(dimethylamino)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]-2-hydroxypyrimidin-4-ylidene}-4-[(4s)-4-(hydroxymethyl)-4-methyl-5-oxoimidazolidin-1-yl]benzamide

C30H42N6O9 (630.3013)

butyl 6-[11-(acetyloxy)-4,7-dihydroxy-3a,6,6,9a,11a-pentamethyl-3,10-dioxo-1h,2h,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxoheptanoate

C36H54O9 (630.3768)

methyl (1s,12s,14r,15z,18s)-12-[(1r,15s,17s,18r)-17-acetyl-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraen-6-yl]-15-ethylidene-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C40H46N4O3 (630.357)

(1s,3r)-4-[(3e,5e,7e,9e)-11-[(2z)-4-[(2r,6s,7ar)-6-hydroxy-4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-2-yl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaen-1-ylidene]-3-hydroxy-3,5,5-trimethylcyclohexyl acetate

C39H50O7 (630.3556)

(2r,3r,4s,5s,6r)-2-{[(1s,4as,5r,8ar)-1,4a-dimethyl-5-[(3e)-3-methyl-5-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pent-3-en-1-yl]-6-methylidene-hexahydro-2h-naphthalen-1-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C32H54O12 (630.3615)

9-{4-benzyl-6-hydroxy-3-oxo-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-9-yl}-6-hydroxy-4-(2-methylpropyl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C37H38N6O4 (630.2954)

(2e,5s,6s)-6-[(1r,3s,3ar,4r,5ar,7s,9as,11ar)-4,7-bis(acetyloxy)-3-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

2-{[1,4a-dimethyl-5-(3-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pent-3-en-1-yl)-6-methylidene-hexahydro-2h-naphthalen-1-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C32H54O12 (630.3615)

(1r,2r,4s,5s,6s,10r,11s,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-(5-oxooxolan-3-yl)-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl 2-methylbutanoate

C35H50O10 (630.3404)

(3e,6r,7r,8e,10z,14z,23s,28z)-4,11,15,29-tetramethyl-19,33,35,37-tetraoxopentacyclo[29.2.2.1⁶,²⁵.1¹⁷,²¹.0⁷,²³]heptatriaconta-1(34),3,8,10,14,17,20,25(36),28,31-decaene-7-carbaldehyde

C42H46O5 (630.3345)

(2z)-4-[(1s,2s,13s)-7-[(2z)-3,7-dimethylocta-2,6-dien-1-yl]-6,8-dihydroxy-17,17-dimethyl-5-(3-methylbut-2-en-1-yl)-10,14-dioxo-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraen-15-yl]-2-methylbut-2-enoic acid

C38H46O8 (630.3193)

(1s,2s,5r,9s)-5-benzyl-1-(3-{[(2s,5r)-3,6-dihydroxy-5-(2-methylpropyl)-2,5-dihydropyrazin-2-yl]methyl}-1h-indol-7-yl)-3-hydroxy-4,7,10-triazatetracyclo[7.7.0.0²,⁷.0¹¹,¹⁶]hexadeca-3,11,13,15-tetraen-6-one

C37H38N6O4 (630.2954)

3-{4'-ethoxy-3,4,5',9',9',14',18'-heptamethyl-5,15'-dioxo-21'-oxaspiro[oxolane-2,20'-pentacyclo[12.8.0.0¹,¹⁷.0⁴,¹³.0⁵,¹⁰]docosan]-8'-yloxy}-3-oxopropanoic acid

C36H54O9 (630.3768)

3-[(1's,2s,3s,4s,4'r,5's,8'r,10's,13's,14's,17'r,18'r)-4'-ethoxy-3,4,5',9',9',14',18'-heptamethyl-5,15'-dioxo-21'-oxaspiro[oxolane-2,20'-pentacyclo[12.8.0.0¹,¹⁷.0⁴,¹³.0⁵,¹⁰]docosan]-8'-yloxy]-3-oxopropanoic acid

C36H54O9 (630.3768)

(1r,4r,7s)-4-benzyl-9-(3-{[(2s,5r)-3,6-dihydroxy-5-(2-methylpropyl)-2,5-dihydropyrazin-2-yl]methyl}-1h-indol-7-yl)-6-hydroxy-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C37H38N6O4 (630.2954)

3,6-diamino-n-(4-amino-5-{[2-({4,7-dihydroxy-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl}amino)-4-hydroxy-5-(c-hydroxycarbonimidoyloxy)-6-(hydroxymethyl)oxan-3-yl]-c-hydroxycarbonimidoyl}pentyl)hexanimidic acid

C25H46N10O9 (630.3449)

10-{[3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy}-2,4a,6a,9,9,12a,14a-heptamethyl-1,3,4,5,6,8,8a,10,11,12,14,14b-dodecahydropicene-2-carboxylic acid

C40H54O6 (630.392)

(2e,5s,6r)-6-[(1r,3s,3ar,4r,5ar,7s,9as,11ar)-3,7-bis(acetyloxy)-4-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

methyl (1s,9s,16s,18r,21r)-6-[(15s,17r,19r)-15-ethyl-1,11-diazapentacyclo[9.6.2.0²,⁷.0⁸,¹⁸.0¹⁵,¹⁹]nonadeca-2,4,6,8(18)-tetraen-17-yl]-2-methyl-2,12-diazahexacyclo[14.2.2.1⁹,¹².0¹,⁹.0³,⁸.0¹⁶,²¹]henicosa-3,5,7-triene-18-carboxylate

C41H50N4O2 (630.3934)

(8z,16e,29z)-8,16,29-trimethyl-13,25,35,38-tetraoxoheptacyclo[25.5.3.2¹¹,¹⁴.1⁶,²⁰.0³,²⁴.0⁵,²².0²⁴,³⁴]octatriaconta-1,8,11,14(37),16,20(36),26,29-octaene-5-carbaldehyde

C42H46O5 (630.3345)

(1r,2r,4s,5s,6s,10r,11s,12r,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-[(3s)-5-oxooxolan-3-yl]-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2r)-2-methylbutanoate

C35H50O10 (630.3404)

(2z)-4-[(1s,2s,13s,15s)-7-[(2z)-3,7-dimethylocta-2,6-dien-1-yl]-6,8-dihydroxy-17,17-dimethyl-5-(3-methylbut-2-en-1-yl)-10,14-dioxo-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraen-15-yl]-2-methylbut-2-enoic acid

C38H46O8 (630.3193)

4-benzyl-9-(3-{[3,6-dihydroxy-5-(2-methylpropyl)-2,5-dihydropyrazin-2-yl]methyl}-1h-indol-7-yl)-6-hydroxy-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C37H38N6O4 (630.2954)

(3r,5s)-3-[(1r,3ar,5as,7s,9as,11as)-9a,11a-dimethyl-2-oxo-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-5-[(2r,3s)-2-isopropyl-3-methyloxiran-2-yl]oxolan-2-one

C35H50O10 (630.3404)

(1r,2r,4as,6as,6br,8ar,9s,10s,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-1-hydroxy-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C36H54O9 (630.3768)

(2e)-4-[(1s,2s,13s,15r)-7-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,8-dihydroxy-17,17-dimethyl-5-(3-methylbut-2-en-1-yl)-10,14-dioxo-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraen-15-yl]-2-methylbut-2-enoic acid

C38H46O8 (630.3193)

(7r,10s,13s,15z,17s,18r)-18-ethyl-6,12-dihydroxy-4-(4-hydroxyphenyl)-7-(1h-indol-3-ylmethyl)-8,10,13,15,17-pentamethyl-1-oxa-5,8,11-triazacyclooctadeca-5,11,15-triene-2,9-dione

C36H46N4O6 (630.3417)

1-[(1r,9r,10r,11r,12e,17s)-12-ethylidene-10-[(1r,9s,12s,13r,14e,19s,21s)-14-ethylidene-10-oxa-8,16-diazahexacyclo[11.5.2.1¹,⁸.0²,⁷.0¹⁶,¹⁹.0¹²,²¹]henicosa-2,4,6-trien-9-yl]-6-hydroxy-8,14-diazapentacyclo[9.5.2.0¹,⁹.0²,⁷.0¹⁴,¹⁷]octadeca-2,4,6-trien-8-yl]ethanone

C40H46N4O3 (630.357)

3-(9a,11a-dimethyl-2-oxo-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl)-5-(2-isopropyl-3-methyloxiran-2-yl)oxolan-2-one

C35H50O10 (630.3404)

2-[8-(acetyloxy)-8a-[(acetyloxy)methyl]-5,6-dimethyl-4-[(2-methylbut-2-enoyl)oxy]-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-5-yl]-1-(5-oxo-2h-furan-3-yl)ethyl 2-methylbut-2-enoate

C34H46O11 (630.304)

12',14-diethyl-14',16-dioxa-8,8',17',19-tetraazaspiro[heptacyclo[10.9.1.1¹,¹⁴.0²,⁷.0⁸,²².0¹⁵,¹⁷.0¹⁹,²³]tricosane-10,10'-hexacyclo[10.7.1.0¹,⁹.0²,⁷.0¹³,¹⁵.0¹⁷,²⁰]icosane]-2,2',4,4',6,6',8'-heptaen-22-ol

C40H46N4O3 (630.357)

4,5-dihydroxy-6-(hydroxymethyl)-3-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl 14-hydroxy-14-(hydroxymethyl)-5,9-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

C31H50O13 (630.3251)

4,5,9,9,13,19,20-heptamethyl-23-oxo-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-en-10-yl 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C40H54O6 (630.392)

(4br,4'bs,8r,8's,8ar,8'as)-2,2'-dihydroxy-1,1'-diisopropyl-4b,4'b,8,8'-tetramethyl-5h,5'h,6h,6'h,7h,7'h,8ah,8'ah,9h,9'h,10h,10'h-[3,3'-biphenanthrene]-8,8'-dicarboxylic acid

C40H54O6 (630.392)

(3r,6s,9s,13r)-6-benzyl-3-[(2r)-butan-2-yl]-5,8,11-trihydroxy-9-(1h-indol-3-ylmethyl)-13-[(2s)-octan-2-yl]-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one

C37H50N4O5 (630.3781)

(2e,5r,6r)-6-[(1r,3s,3ar,4r,5ar,7r,9ar,11as)-4,7-bis(acetyloxy)-3-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

(3r,6e)-2-hydroxy-2,6-dimethyl-8-[(2-oxochromen-7-yl)oxy]oct-6-en-3-yl (2e)-3-(4-{[(2e)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-2-hydroxyphenyl)prop-2-enoate

C38H46O8 (630.3193)

6-benzyl-5,8,11-trihydroxy-9-(1h-indol-3-ylmethyl)-13-(octan-2-yl)-3-(sec-butyl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one

C37H50N4O5 (630.3781)

(2e,5s,6s)-6-[(1r,3s,3ar,4r,5ar,7s,9as,11ar)-3,7-bis(acetyloxy)-4-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)